Canadian CanadaBis Reports C$3.97M Net Revenue In Q3 2024, 26% Decline YoY
Canadian CanadaBis Reports C$3.97M Net Revenue In Q3 2024, 26% Decline YoY
See also: Canadian Vs. U.S. Cannabis Companies: Who Is Winning The Market Race To Weed Profits? Alberta-based vertically integrated cannabis operator CanadaBis (CVE:CANB) announced the results from their Q3 2024 for the company and its subsidiaries Stigma Pharmaceuticals Inc., Stigma Grow, Stigma Roots, Indicative Collection and Goldstream Cannabis Inc.
总部位于艾伯塔省的大麻制造业垂直一体化运营商CanadaBis(CVE:CANB)宣布了公司及其子公司Stigma药品公司，Stigma种植园，Stigma根系植物，Indicative Collection和Goldstream Cannabis Inc. 的2024财年第三季度财报。
Despite showing a decrease of 26% YoY for Q3, the company highlighted the fact that it is its tenth consecutive quarter generating revenue. The positive results come amid a challenging economy for Cannabis in Canada, which pushed the company to seek increased operational efficiency.
尽管第三季度按年计算下降26％，公司强调这是第十个连续营收季度。积极的结果出现在对加拿大大麻经济挑战的背景下，这促使公司寻求提高运营效率。
"Canadabis Capital's performance in Q3 2024 was robust, driven by our strategic investments and continuous efforts to optimize our operational efficiencies," said CEO Travis Mcintyre.
"Canadabis Capital在2024财年第三季度的表现强劲，受战略投资和持续优化运作效率的推动，"首席执行官Travis Mcintyre表示。
Q3 2024 Financial Results Compared To Q3 2023
2024 Q3 财务业绩与2023 Q3相比
- Gross Revenue: For the three months ended April 30, 2024, gross revenue was $7.08 million compared to $9.59 million for the same period in 2023, marking a decrease of 26%.
- Net Revenue: Net revenue followed a similar trend, decreasing to $3.97 million from $6.05 million year over year, influenced by both the excise duty adjustments and market dynamics.
- Cost of Sales: Cost of sales saw a slight decline to $1.80 million from $3.35 million, reflecting improved cost management strategies.
- Gross Profit: Gross profit was $2.17 million for the recent quarter, down from $2.70 million in 2023, demonstrating tighter revenue conditions.
- Net Income: Net income for the three months saw a decrease to $109,824, compared to $1.20 million in 2023.
- EBITDA: Adjusted EBITDA decreased to $497,663 from $1.53 million, aligning with the observed reductions in gross profit and net income
- 毛收入：截至2024年4月30日的三个月内，毛收入为708万美元，相比之下，2023年同期为959万美元，下降了26％。
- 净收入：净收入呈相似的趋势下降，由于消费税调整和市场动态的影响，从去年同期的605万美元降至397万美元。
- 销售成本：销售成本略有下降，由去年同期的335万美元下降到180万美元，反映了改善的成本管理策略。
- 毛利润：最近一个季度的毛利润为217万美元，低于2023年的270万美元，表明更加严格的收入条件。
- 净利润：最近三个月的净利润下降至10.9万美元，相比之下，2023年为120万美元。
- 调整后的EBITDA从153万美元下降到49.8万美元，与毛利润和净利润的观察到的下降相一致。
See also: Canadian Vs. U.S. Cannabis Companies: Who Is Winning The Market Race To Weed Profits?
另请参阅：加拿大与美国的大麻公司：谁在大麻市场的竞赛中获得了胜利？
As for operational highlights, CanadaBis launched Canada's first 60% THC pre-roll. The company reported on significant investment in research and development to enhance its product lineup and manufacturing techniques; and formed a strategic partnership with a Portuguese distribution company to expand in the european market.
至于运营亮点，CanadaBis推出了加拿大首个60％ THC预卷烟。该公司报告了在研究和开发方面的重大投资，以增强其产品阵容和制造技术。此外还与葡萄牙的分销公司合作，以扩大在欧洲市场的影响力。
CanadaBis Stock Action
CanadaBis的股票行情
CanadaBis Stock is trading at $0.0650 at the moment of this writing, down 13.3% from Tuesday.
此时CanadaBis的股票价格为0.0650美元，比星期二下降了13.3％。
译文内容由第三方软件翻译。
